CD4 and inflammatory bowel disease: (21) revealed that the percentages of resting Tregs, activated Tregs, total Tregs, and type-1 regulatory like T cells among CD4+ cells all performed well in the prediction of the clinical response to IFX 14–22 weeks after the start of therapy in patients with IBD.